UBS Group’s Purple Biotech PPBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $400 | Sell |
99
-211
| -68% | -$1.14K | ﹤0.01% | 9917 |
|
|
2025
Q4 | $2.04K | Sell |
310
-285
| -48% | -$2.07K | ﹤0.01% | 9395 |
|
|
2025
Q3 | $3.41K | Sell |
595
-1,719
| -74% | -$30.8K | ﹤0.01% | 9051 |
|
|
2025
Q2 | $54.3K | Buy |
2,314
+11
| +0.5% | +$272 | ﹤0.01% | 7703 |
|
|
2025
Q1 | $61.2K | Buy |
2,303
+1,225
| +114% | +$39.2K | ﹤0.01% | 7426 |
|
|
2024
Q4 | $50.6K | Buy |
+1,078
| New | +$41.5K | ﹤0.01% | 7283 |
|
|
2024
Q3 | – | Sell |
-64
| Closed | -$5.23K | – | 9937 |
|
|
2024
Q2 | $5.23K | Buy |
64
+6
| +10% | +$696 | ﹤0.01% | 8016 |
|
|
2024
Q1 | $7.78K | Buy |
58
+48
| +480% | +$6.88K | ﹤0.01% | 7362 |
|
|
2023
Q4 | $1.56K | Buy |
10
+1
| +11% | +$221 | ﹤0.01% | 8273 |
|
|
2023
Q3 | $2.22K | Buy |
+9
| New | +$2.14K | ﹤0.01% | 7742 |
|
|
2023
Q2 | – | Sell |
-23
| Closed | -$8.17K | – | 9472 |
|
|
2023
Q1 | $8.17K | Sell |
23
-18
| -44% | -$6.75K | ﹤0.01% | 7750 |
|
|
2022
Q4 | $11.4K | Sell |
41
-12
| -23% | -$4.61K | ﹤0.01% | 8399 |
|
|
2022
Q3 | $21K | Buy |
53
+30
| +130% | +$14K | ﹤0.01% | 7334 |
|
|
2022
Q2 | $11K | Buy |
23
+13
| +130% | +$7.79K | ﹤0.01% | 7831 |
|
|
2022
Q1 | $8K | Sell |
10
-5
| -33% | -$3.23K | ﹤0.01% | 8691 |
|
|
2021
Q4 | $12K | Sell |
15
-5
| -25% | -$4.26K | ﹤0.01% | 8572 |
|
|
2021
Q3 | $19K | Sell |
20
-86
| -81% | -$83.3K | ﹤0.01% | 7217 |
|
|
2021
Q2 | $104K | Buy |
106
+15
| +16% | +$13.8K | ﹤0.01% | 5850 |
|
|
2021
Q1 | $75K | Sell |
91
-12
| -12% | -$11.2K | ﹤0.01% | 6187 |
|
|
2020
Q4 | $79K | Buy |
103
+91
| +758% | +$76.7K | ﹤0.01% | 5847 |
|
|
2020
Q3 | $11K | Sell |
12
-130
| -92% | -$161K | ﹤0.01% | 6776 |
|
|
2020
Q2 | $315K | Buy |
142
+127
| +847% | +$125K | ﹤0.01% | 4483 |
|
|
2020
Q1 | $9K | Buy |
15
+11
| +275% | +$13.5K | ﹤0.01% | 7005 |
|
|
2019
Q4 | $6K | Buy |
4
+3
| +300% | +$4.38K | ﹤0.01% | 7526 |
|
|
2019
Q3 | $1K | Hold |
1
| – | – | ﹤0.01% | 7850 |
|
|
2019
Q2 | $1K | Hold |
1
| – | – | ﹤0.01% | 7729 |
|
|
2019
Q1 | $3K | Sell |
1
-1
| -50% | -$2.41K | ﹤0.01% | 7343 |
|
|
2018
Q4 | $2K | Buy |
2
+1
| +100% | +$2.52K | ﹤0.01% | 7808 |
|
|
2018
Q3 | $2K | Sell |
1
-1
| -50% | -$3.95K | ﹤0.01% | 7744 |
|
|
2018
Q2 | $10K | Hold |
2
| – | – | ﹤0.01% | 7140 |
|
|
2018
Q1 | $10K | Hold |
2
| – | – | ﹤0.01% | 6871 |
|
|
2017
Q4 | $10K | Buy |
+2
| New | +$8.93K | ﹤0.01% | 7030 |
|
|
2017
Q3 | – | Sell |
-2
| Closed | -$6K | – | 7929 |
|
|
2017
Q2 | $6K | Sell |
2
-2
| -50% | -$7.29K | ﹤0.01% | 7056 |
|
|
2017
Q1 | $15K | Buy |
4
+3
| +300% | +$14.3K | ﹤0.01% | 6353 |
|
|
2016
Q4 | $5K | Buy |
+1
| New | +$6.96K | ﹤0.01% | 7247 |
|
|
2016
Q3 | – | Sell |
-1
| Closed | -$8K | – | 7873 |
|
|
2016
Q2 | $8K | Hold |
1
| – | – | ﹤0.01% | 6904 |
|
|
2016
Q1 | $11K | Hold |
1
| – | – | ﹤0.01% | 6604 |
|
|
2015
Q4 | $6K | Buy |
+1
| New | +$6.27K | ﹤0.01% | 7617 |
|
Other funds holding PPBT
SP
GI
SS
ASN
UBS Group's PPBT Position: Q1 2026 in Review
UBS Group reduced its Purple Biotech (PPBT) stake by 68% in Q1 2026, selling an estimated $1.14K and leaving 99 shares worth $400. The position accounts for ﹤0.01% of the portfolio, ranked #9917.
UBS Group first reported a position in PPBT in Q4 2015 and has held it in 38 quarters since. The position peaked at $315K in Q2 2020. 15 funds tracked by Wall St. Rank hold PPBT as of Q1 2026.
- UBS Group held 99 shares of Purple Biotech worth $400 as of Q1 2026.
- UBS Group sold 211 Purple Biotech shares in Q1 2026, an estimated $1.14K.
- Purple Biotech made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9917 holding.
- UBS Group first reported a position in Purple Biotech in Q4 2015 and has held it in 38 quarters since.
- UBS Group's Purple Biotech position peaked at $315K in Q2 2020.
- 15 funds tracked by Wall St. Rank held Purple Biotech as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.